 multicent long-term safeti efficaci studi vigabatrin refractori complex partial seizur updat patient refractori complex partial seizur favor initi respons median month thirty-seven patient vigabatrin follow reason benefit-to-risk evalu seizur breakthrough advers event seizur breakthrough advers event elig studi non-drug-rel death narcot abus patient request signific abnorm laboratori studi sma complet blood count ecg eeg visual respons test toxic revers dose-depend side effect long-term data clinic trial vigabatrin unit canada